口服避孕药与输卵管结扎与早绝经风险的关系
结果显示口服避孕药使用与早绝经风险无关,而输卵管结扎与风险轻度升高相关(HR=1.17,95%CI 1.06-1.28)。
要点
- 口服避孕药的使用时长、时机和类型均与早绝经风险无显著关联。
- 输卵管结扎与早绝经风险轻度升高相关(HR=1.17,95%CI 1.06-1.28)。
- 口服避孕药使用未显示对早绝经风险有实质性危害或获益。
核心结论
- 未观察到口服避孕药使用与早绝经风险存在关联,但输卵管结扎与风险轻度升高相关。
主要发现
- 与从未使用口服避孕药者相比,使用120个月及以上者早绝经HR为1.01(95%CI 0.87-1.17;趋势P=0.71)。
- 输卵管结扎与早绝经风险升高相关(HR=1.17,95%CI 1.06-1.28)。
临床怎么用
- 咨询时可告知女性口服避孕药使用与早绝经风险无关。
- 输卵管结扎者早绝经风险轻度升高,可据此进行个体化咨询。
局限性
- 研究人群在种族和民族方面同质性较高,需在更多样化人群中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the association of oral contraceptives (OCs) and tubal ligation (TL) with early natural menopause? SUMMARY ANSWER: We did not observe an association of OC use with risk of early natural menopause; however, TL was associated with a modestly higher risk. WHAT IS KNOWN ALREADY: OCs manipulate hormone levels, prevent ovulation, and may modify the rate of follicular atresia, while TL may disrupt the blood supply to the ovaries. These mechanisms may be associated with risk of early menopause, a condition associated with increased risk of cardiovascular disease and other adverse health outcomes. STUDY DESIGN, SIZE, DURATION: We examined the association of OC use and TL with natural menopause before the age of 45 years in a population-based study within the prospective Nurses' Health Study II (NHSII) cohort. Participants were followed from 1989 to 2017 and response rates were 85-90% for each cycle. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants included 106 633 NHSII members who were premenopausal and aged 25-42 years at baseline. Use, duration and type of OC, and TL were measured at baseline and every 2 years. Menopause status and age were assessed every 2 years. Follow-up continued until early menopause, age 45 years, hysterectomy, oophorectomy, death, cancer diagnosis, or loss to follow-up. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CIs adjusted for lifestyle, dietary, and reproductive factors. MAIN RESULTS AND THE ROLE OF CHANCE: Over 1.6 million person-years, 2579 members of the analytic cohort experienced early natural menopause. In multivariable models, the duration, timing, and type of OC use were not associated with risk of early menopause. For example, compared with women who never used OCs, those reporting 120+ months of OC use had an HR for early menopause of 1.01 (95% CI, 0.87-1.17; P for trend=0.71). TL was associated with increased risk of early menopause (HR = 1.17, 95% CI, 1.06-1.28). LIMITATIONS, REASONS FOR CAUTION: Our study population is homogenous with respect to race and ethnicity. Additional evaluation of these relations in more diverse populations is important. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this is the largest study examining the association of OC use and TL with early natural menopause to date. While TL was associated with a modest higher risk of early menopause, our findings do not support any material hazard or benefit for the use of OCs. STUDY FUNDING/COMPETING INTEREST(S): The study was sponsored by UO1CA176726 and R01HD078517 from the National Institutes of Health and Department of Health and Human Services. The work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The authors have no competing interests to report. TRIAL REGISTRATION NUMBER: N/A.
引用
- Langton CR, Whitcomb BW, Purdue-Smithe AC, et al. Association of oral contraceptives and tubal ligation with risk of early natural menopause. Hum Reprod. 2021. PMID: 33822044. doi:10.1093/humrep/deab054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。